Even though the medical relevance from the aforementioned cardiovascular chance factor alterations by tirzepatide is going to be assessed inside the planned cardiovascular result study SURPASS-CVOT ( "type":"scientific-trial","attrs": "text":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Assessment indicated that tirzepatide didn't boost the po... https://amseries32985.jaiblogs.com/55032268/article-under-review